You're getting the same active ingredient with less regulatory oversight
No extras, like promotional materials, branded swag, or nausea medication, were included
Exploratory outcomes The reduction in weight was correlated with the improvements in time in range (Pearson = 0.50, P = 0.015) and HbA1c (Pearson = 0.43, P = 0.04
The demonstrated success with liraglutide, a commercially significant peptide therapeutic, makes this particularly relevant for organizations considering their manufacturing strategy in the growing GLP-1 market
4 Discussion The main findings of the present studies are the following: (1) the pharmacokinetics of icodec are unchanged when combining icodec and semaglutide in IcoSema, (2) the total exposure of semaglutide in IcoSema is unchanged, but the maximum concentration is higher and earlier compared with semaglutide administration alone, (3) the change in semaglutide pharmacokinetics in IcoSema appears to be owing to competition for albumin binding locally at the injection site, where icodec outcompetes semaglutide and (4) the frequency of gastrointestinal related adverse events is higher for IcoSema versus icodec or semaglutide administration alone
